To evaluate the clinical significance of UFT-cisplatin neoadjuvant in patients with locally advanced cervical cancer, we compared the response rate and the toxicity of UFT-cisplatin(UFT-P) chemotherapy with those of 5-FU, cisplatin(FP)
chemotherapy.
Between January 1989 and February 1993, 21 patients with locally advanced cervical carcinoma(FIGO Ib-IIb) initially were treated with two or three courses of UFT-cisplatin neoadjuvant chemotherapy and 22 patients were treated with FP neoadjuvant
chemotherapy.
@ES The results were obtained as follows.
@EN 1. The clinical response rate to UFT-P chemotherapy(overall; 81.0%, complete response; 4.8%, partial response; 76.2%) was higher than FP chemotherapy(overall; 59.1%, partial response; 59.1%), but there was no statistical difference(p=o.185).
2. There were no significant difference between UFT-P and FP chemotherapy according to the post-operative pathologic results(cervical involvement, parametrium involvement, resection margin, lymph ode metastasis, lymphovascular space invasion).
3. There were higher incidence of granulocytopenia and diarrhea in UFT-P chemotherapy than FP chemotherapy. So these data suggest that UFT-P neoadjuvant chemotherapy may be clinically useful as a neoadjuvant chemotherapy in uterine cervical
carcinoma
due to its high rate, short hospitalization day and convinience of administration.
|